ANAB
ANAB clinical trials: ANAPTYSBIO, INC
Every trial on ClinicalTrials.gov where ANAPTYSBIO, INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 8
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ANAB on the catalyst calendar · ANAB registry changes
- Primary completion Jan 2026Sponsor estimatePhase 2NCT06127043A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)AnaptysBio, Inc. · Ulcerative ColitisActive, not recruitingANABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 16, 2024ActualPhase 2NCT05935085This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).AnaptysBio, Inc. · Atopic Dermatitis EczemaTerminatedANABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 29, 2024Sponsor estimatePhase 2NCT06041269A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)AnaptysBio, Inc. · Rheumatoid ArthritisActive, not recruitingANABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2018ActualPhase 2NCT03469934Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic AsthmaAnaptysBio, Inc. · Eosinophilic AsthmaCompletedANABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2018ActualPhase 2NCT02920021Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut AllergyAnaptysBio, Inc. · Peanut AllergyCompletedANABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2019ActualPhase 2NCT03533751Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic DermatitisAnaptysBio, Inc. · Atopic DermatitisCompletedANABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2023Sponsor estimatePhase 2NCT05205070A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia AreataAnaptysBio, Inc. · Alopecia AreataUnknown statusANABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2, 2020ActualPhase 2NCT03614923Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)AnaptysBio, Inc. · Chronic RhinosinusitisCompletedANABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2018ActualNo phase registeredNCT04256044Analysis of Peripheral Blood ILC2s and Th2 Cells in Response to ANB020University of Leicester · AsthmaCompletedANABCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner